Jazz Pharmaceuticals (JAZZ) Gains from Investment Securities (2010 - 2026)

Jazz Pharmaceuticals' Gains from Investment Securities history runs 17 years deep, the most recent figure standing at $103.6 million for Q1 2026.

• In Q1 2026, Gains from Investment Securities rose 1493.85% year-over-year to $103.6 million; the TTM figure through Mar 2026 stood at $94.0 million (up 703.78% YoY), while the FY2025 annual figure was -$3.1 million, up 82.74% from the prior year.
• Gains from Investment Securities was $103.6 million for Q1 2026 at Jazz Pharmaceuticals, up from $5.0 million in the prior quarter.
• In the past five years, Gains from Investment Securities ranged from a high of $103.6 million in Q1 2026 to a low of -$77.5 million in Q3 2025.
• Historically, Gains from Investment Securities has averaged $8.7 million across 5 years, with a median of $4.2 million in 2023.
• The sharpest annual moves came in 2024 and 2025: Gains from Investment Securities tumbled 1443.63% in 2024, then jumped 3810.01% in 2025.
• A 5-year view of Gains from Investment Securities shows it stood at $10.5 million in 2022, then slumped by 84.6% to $1.6 million in 2023, then gained by 1.43% to $1.6 million in 2024, then jumped by 202.69% to $5.0 million in 2025, then jumped by 1990.82% to $103.6 million in 2026.
• The last three Gains from Investment Securities figures came in at $103.6 million (Q1 2026), $5.0 million (Q4 2025), and -$77.5 million (Q3 2025), per Business Quant data.